Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. Social Networks
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. Hosting Providers
  14. CDN Services

We began analyzing https://www.nature.com/articles/onc2012128, but it redirected us to https://www.nature.com/articles/onc2012128. The analysis below is for the second page.

Title[redir]:
Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer | Oncogene
Description:
Epithelial–mesenchymal transition (EMT) is an initiating event in tumor cell invasion and metastasis. It has been shown to occur in resistance to a range of cancer therapies, including tamoxifen. MicroRNAs (miRNAs) have been associated with EMT as well as resistance to standard therapies. To investigate the role of miRNAs in the development of resistance to tamoxifen as well as accompanying EMT-like properties, we established a tamoxifen-resistant (TamR) model by continually exposing MCF-7 breast cancer cells to tamoxifen. In addition to the molecular changes known to be involved in acquired tamoxifen resistance, TamR cells displayed mesenchymal features and had increased invasiveness. Genome-wide miRNA microarray analysis revealed that miRNA-375 was among the top downregulated miRNAs in resistant cells. Re-expression of miR-375 was sufficient to sensitize TamR cells to tamoxifen and partly reversed EMT. A combination of mRNA profiling, bioinformatics analysis and experimental validation identified metadherin (MTDH) as a direct target of miR-375. Knockdown of MTDH partially phenocopied the effects of miR-375 on the sensitivity to tamoxifen and the reversal of EMT. We observed an inverse correlation between the expression of miR-375 and its target MTDH in primary breast cancer samples, implying the pathological relevance of targeting. Finally, tamoxifen-treated patients with higher expression of MTDH had a shorter disease-free survival and higher risk of relapse. As most cancer-related deaths occur because of resistance to standard therapies and metastasis, re-expression of miR-375 or targeting MTDH might serve as potential therapeutic approaches for the treatment of TamR breast cancer.

Matching Content Categories {📚}

  • Science
  • Education
  • Health & Fitness

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We can't see how the site brings in money.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Doi.org has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

cells, mirna, tamr, cancer, tamoxifen, mtdh, expression, cell, breast, resistance, article, figure, mcf, google, scholar, cas, mirnas, emt, invasion, data, patients, shown, results, properties, compared, epithelial, emtlike, mesenchymal, genes, luciferase, assay, target, lines, significantly, supplementary, reduced, nature, reexpression, ecadherin, effects, higher, potential, viability, usa, analysis, mrna, direct, targeting, survival, line,

Topics {✒️}

nature portfolio privacy policy nature 1978 nature advertising gov/index er/her2-positive breast cancer social media translational research sciences high erbb2/her2-expressing patients 0/ reprints mirna-overexpression vectors pcmv-mirs epithelial–mesenchymal transition epithelial-mesenchymal transition creative commons attribution-noncommercial pharmaceutical research kaplan–meier survival curves tight cell–cell junctions total dna content anti-e-cadherin antibody poor-prognosis breast cancer hrp-conjugated secondary antibodies tight cell–cell contacts cancer-related deaths occur cancer-relevant deaths arise received tamoxifen monotherapy hoffmann-la roche limited luciferase-based viability assay hormone receptor-positive patients e-cadherin predominantly localized normalize qrt–pcr data benjamini–hochberg adjusted p author correspondence large gene-targeting spectrum review article epithelial poorer disease-free survival differentially expressed micrornas research ec50 dose-response analysis qrt–pcr data validation shorter disease-free survival dose-response curves showed poorer relapse-free survival hek-293ft cell line downregulating e-cadherin expression anchorage-independent growth capacity therapeutic strategies potential therapeutic approaches qrt–pcr data show absolute log fold-change

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer
         description:Epithelial–mesenchymal transition (EMT) is an initiating event in tumor cell invasion and metastasis. It has been shown to occur in resistance to a range of cancer therapies, including tamoxifen. MicroRNAs (miRNAs) have been associated with EMT as well as resistance to standard therapies. To investigate the role of miRNAs in the development of resistance to tamoxifen as well as accompanying EMT-like properties, we established a tamoxifen-resistant (TamR) model by continually exposing MCF-7 breast cancer cells to tamoxifen. In addition to the molecular changes known to be involved in acquired tamoxifen resistance, TamR cells displayed mesenchymal features and had increased invasiveness. Genome-wide miRNA microarray analysis revealed that miRNA-375 was among the top downregulated miRNAs in resistant cells. Re-expression of miR-375 was sufficient to sensitize TamR cells to tamoxifen and partly reversed EMT. A combination of mRNA profiling, bioinformatics analysis and experimental validation identified metadherin (MTDH) as a direct target of miR-375. Knockdown of MTDH partially phenocopied the effects of miR-375 on the sensitivity to tamoxifen and the reversal of EMT. We observed an inverse correlation between the expression of miR-375 and its target MTDH in primary breast cancer samples, implying the pathological relevance of targeting. Finally, tamoxifen-treated patients with higher expression of MTDH had a shorter disease-free survival and higher risk of relapse. As most cancer-related deaths occur because of resistance to standard therapies and metastasis, re-expression of miR-375 or targeting MTDH might serve as potential therapeutic approaches for the treatment of TamR breast cancer.
         datePublished:2012-04-16T00:00:00Z
         dateModified:2012-04-16T00:00:00Z
         pageStart:1173
         pageEnd:1182
         sameAs:https://doi.org/10.1038/onc.2012.128
         keywords:
            Breast cancer
            Cancer therapeutic resistance
            Epithelial–mesenchymal transition
            miRNAs
            microRNAs
            tamoxifen resistance
            epithelial–mesenchymal transition
            breast cancer
            metadherin
            Medicine/Public Health
            general
            Internal Medicine
            Cell Biology
            Human Genetics
            Oncology
            Apoptosis
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2012.128/MediaObjects/41388_2013_Article_BFonc2012128_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2012.128/MediaObjects/41388_2013_Article_BFonc2012128_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2012.128/MediaObjects/41388_2013_Article_BFonc2012128_Fig3_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2012.128/MediaObjects/41388_2013_Article_BFonc2012128_Fig4_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2012.128/MediaObjects/41388_2013_Article_BFonc2012128_Fig5_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2012.128/MediaObjects/41388_2013_Article_BFonc2012128_Fig6_HTML.jpg
         isPartOf:
            name:Oncogene
            issn:
               1476-5594
               0950-9232
            volumeNumber:32
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group UK
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:A Ward
               affiliation:
                     name:German Cancer Research Center (DKFZ)
                     address:
                        name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:A Balwierz
               affiliation:
                     name:German Cancer Research Center (DKFZ)
                     address:
                        name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:J D Zhang
               affiliation:
                     name:German Cancer Research Center (DKFZ)
                     address:
                        name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:M Küblbeck
               affiliation:
                     name:German Cancer Research Center (DKFZ)
                     address:
                        name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Y Pawitan
               affiliation:
                     name:Karolinska Institute
                     address:
                        name:Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
               name:T Hielscher
               affiliation:
                     name:German Cancer Research Center (DKFZ)
                     address:
                        name:Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:S Wiemann
               affiliation:
                     name:German Cancer Research Center (DKFZ)
                     address:
                        name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ö Sahin
               affiliation:
                     name:German Cancer Research Center (DKFZ)
                     address:
                        name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer
      description:Epithelial–mesenchymal transition (EMT) is an initiating event in tumor cell invasion and metastasis. It has been shown to occur in resistance to a range of cancer therapies, including tamoxifen. MicroRNAs (miRNAs) have been associated with EMT as well as resistance to standard therapies. To investigate the role of miRNAs in the development of resistance to tamoxifen as well as accompanying EMT-like properties, we established a tamoxifen-resistant (TamR) model by continually exposing MCF-7 breast cancer cells to tamoxifen. In addition to the molecular changes known to be involved in acquired tamoxifen resistance, TamR cells displayed mesenchymal features and had increased invasiveness. Genome-wide miRNA microarray analysis revealed that miRNA-375 was among the top downregulated miRNAs in resistant cells. Re-expression of miR-375 was sufficient to sensitize TamR cells to tamoxifen and partly reversed EMT. A combination of mRNA profiling, bioinformatics analysis and experimental validation identified metadherin (MTDH) as a direct target of miR-375. Knockdown of MTDH partially phenocopied the effects of miR-375 on the sensitivity to tamoxifen and the reversal of EMT. We observed an inverse correlation between the expression of miR-375 and its target MTDH in primary breast cancer samples, implying the pathological relevance of targeting. Finally, tamoxifen-treated patients with higher expression of MTDH had a shorter disease-free survival and higher risk of relapse. As most cancer-related deaths occur because of resistance to standard therapies and metastasis, re-expression of miR-375 or targeting MTDH might serve as potential therapeutic approaches for the treatment of TamR breast cancer.
      datePublished:2012-04-16T00:00:00Z
      dateModified:2012-04-16T00:00:00Z
      pageStart:1173
      pageEnd:1182
      sameAs:https://doi.org/10.1038/onc.2012.128
      keywords:
         Breast cancer
         Cancer therapeutic resistance
         Epithelial–mesenchymal transition
         miRNAs
         microRNAs
         tamoxifen resistance
         epithelial–mesenchymal transition
         breast cancer
         metadherin
         Medicine/Public Health
         general
         Internal Medicine
         Cell Biology
         Human Genetics
         Oncology
         Apoptosis
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2012.128/MediaObjects/41388_2013_Article_BFonc2012128_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2012.128/MediaObjects/41388_2013_Article_BFonc2012128_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2012.128/MediaObjects/41388_2013_Article_BFonc2012128_Fig3_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2012.128/MediaObjects/41388_2013_Article_BFonc2012128_Fig4_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2012.128/MediaObjects/41388_2013_Article_BFonc2012128_Fig5_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2012.128/MediaObjects/41388_2013_Article_BFonc2012128_Fig6_HTML.jpg
      isPartOf:
         name:Oncogene
         issn:
            1476-5594
            0950-9232
         volumeNumber:32
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group UK
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:A Ward
            affiliation:
                  name:German Cancer Research Center (DKFZ)
                  address:
                     name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:A Balwierz
            affiliation:
                  name:German Cancer Research Center (DKFZ)
                  address:
                     name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:J D Zhang
            affiliation:
                  name:German Cancer Research Center (DKFZ)
                  address:
                     name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M Küblbeck
            affiliation:
                  name:German Cancer Research Center (DKFZ)
                  address:
                     name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Y Pawitan
            affiliation:
                  name:Karolinska Institute
                  address:
                     name:Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
            name:T Hielscher
            affiliation:
                  name:German Cancer Research Center (DKFZ)
                  address:
                     name:Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:S Wiemann
            affiliation:
                  name:German Cancer Research Center (DKFZ)
                  address:
                     name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ö Sahin
            affiliation:
                  name:German Cancer Research Center (DKFZ)
                  address:
                     name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Oncogene
      issn:
         1476-5594
         0950-9232
      volumeNumber:32
Organization:
      name:Nature Publishing Group UK
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:German Cancer Research Center (DKFZ)
      address:
         name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
         type:PostalAddress
      name:German Cancer Research Center (DKFZ)
      address:
         name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
         type:PostalAddress
      name:German Cancer Research Center (DKFZ)
      address:
         name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
         type:PostalAddress
      name:German Cancer Research Center (DKFZ)
      address:
         name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
         type:PostalAddress
      name:Karolinska Institute
      address:
         name:Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
         type:PostalAddress
      name:German Cancer Research Center (DKFZ)
      address:
         name:Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany
         type:PostalAddress
      name:German Cancer Research Center (DKFZ)
      address:
         name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
         type:PostalAddress
      name:German Cancer Research Center (DKFZ)
      address:
         name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:A Ward
      affiliation:
            name:German Cancer Research Center (DKFZ)
            address:
               name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
               type:PostalAddress
            type:Organization
      name:A Balwierz
      affiliation:
            name:German Cancer Research Center (DKFZ)
            address:
               name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
               type:PostalAddress
            type:Organization
      name:J D Zhang
      affiliation:
            name:German Cancer Research Center (DKFZ)
            address:
               name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
               type:PostalAddress
            type:Organization
      name:M Küblbeck
      affiliation:
            name:German Cancer Research Center (DKFZ)
            address:
               name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
               type:PostalAddress
            type:Organization
      name:Y Pawitan
      affiliation:
            name:Karolinska Institute
            address:
               name:Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
               type:PostalAddress
            type:Organization
      name:T Hielscher
      affiliation:
            name:German Cancer Research Center (DKFZ)
            address:
               name:Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany
               type:PostalAddress
            type:Organization
      name:S Wiemann
      affiliation:
            name:German Cancer Research Center (DKFZ)
            address:
               name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
               type:PostalAddress
            type:Organization
      name:Ö Sahin
      affiliation:
            name:German Cancer Research Center (DKFZ)
            address:
               name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
      name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
      name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
      name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
      name:Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
      name:Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany
      name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
      name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany

Social Networks {👍}(1)

External Links {🔗}(251)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Prism.js
  • Zoom.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {📦}

  • Crossref

5.64s.